Roche returns rights on ORY-1001
As reported yesterday, Roche has decided to discontinue the development of ORY-1001 (a selective LSD1 inhibitor) and return the rights to Oryzon,...
163 Views
ORY-2001 and ORY-3001 next in focus
Oryzon’s Q117 financial results were broadly in line with our expectations. The company’s partner, Roche is now solely responsible for ORY-1001’s...
207 Views
Maturing epigenetics portfolio
Oryzon has been making steady progress with its epigenetics R&D pipeline. Following positive Phase I/IIa trial results in December 2016,...
109 Views
New data further back MS indication
Oryzon has two assets, ORY-1001 and ORY-2001, in the clinical stage of development, with ORY-3001 being investigated for oncology indications in...
116 Views
Expanding clinical R&D pipeline
Oryzon presented more granular data from Phase I/IIa in acute leukaemia at the American Society of Hematology (ASH) meeting after the positive...
84 Views